1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Coherus Aims To Pull Out $75m In Costs Amid Conservative 2023 Guidance

Three Launches Eyed Next Year, Alongside Recent Ranibizumab Biosimilar

 
• By Dean Rudge

Coherus BioSciences saw its Q3 revenues tumble by 45% as it arrived at the firm’s projected nadir. A swathe of launches and a cost-cutting program are targeted to bring the firm back to profitability in 2024.

Profit (Cagkan Sayin/Alamy Stock Photo)
Coherus is projecting a return to profitability in 2024 • Source: Shutterstock (Alamy Stock Photo)

With operating losses exceeding $205m in the first nine months of the year amid a long-expected inflection point for the company’s top line, Coherus BioSciences has announced plans to take out $75m in costs in 2023 in order to steady the ship ahead of new and future launches.

“We continue our efforts to identify efficiencies in the business and reduce expenditures

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business